Beveridge C, Hermanns C, Thanawala S, Yang Q, Qin Y, Thota P
    
    
    Dig Dis Sci. 2025; .
  
  
    PMID: 40024960
    
    
          DOI: 10.1007/s10620-025-08874-7.
      
 
                                  
  
    Hasosah M, Sukkar G, AlSahafi A, Zaidan A, Ghous N, Alshahrani A
    
    
    BMC Pediatr. 2025; 25(1):100.
  
  
    PMID: 39910505
    
          PMC: 11796247.
    
          DOI: 10.1186/s12887-024-05313-w.
      
 
                                  
  
    Lutzu N, Favale A, Demurtas M, Del Giacco S, Onali S, Fantini M
    
    
    Front Med (Lausanne). 2025; 11:1513417.
  
  
    PMID: 39906352
    
          PMC: 11790572.
    
          DOI: 10.3389/fmed.2024.1513417.
      
 
                                  
  
    Fetz A, Hemy A, Kim H, Moosavi S
    
    
    J Can Assoc Gastroenterol. 2025; 8(1):13-20.
  
  
    PMID: 39906276
    
          PMC: 11788507.
    
          DOI: 10.1093/jcag/gwae033.
      
 
                                  
  
    Ketchem C, Lynch K
    
    
    Gastroenterol Hepatol (N Y). 2025; 20(12):733-738.
  
  
    PMID: 39886002
    
          PMC: 11776008.
    
      
 
                              
              
                              
                                      
  The clinical impact of conventional therapies for adults and adolescents suffering from eosinophilic esophagitis, a type 2 inflammatory chronic disease, and their economic consequences in Italy: Systematic literature review and meta-analysis.
  
    Canonica G, Mazziotti G, Repici A, Povero M, Castello L, Pradelli L
    
    
    J Allergy Clin Immunol Glob. 2025; 4(1):100383.
  
  
    PMID: 39877128
    
          PMC: 11773236.
    
          DOI: 10.1016/j.jacig.2024.100383.
      
 
                                          
                                                          
  Assessment of Disease Activity in Eosinophilic Esophagitis: Is It Clinically Relevant or Simply an Amusement for Experts?.
  
    Safroneeva E, Schoepfer A
    
    
    Inflamm Intest Dis. 2025; 10(1):10-17.
  
  
    PMID: 39810959
    
          PMC: 11731911.
    
          DOI: 10.1159/000542470.
      
 
                                          
                                                          
  Effect of randomized treatment withdrawal of budesonide oral suspension on clinically relevant efficacy outcomes in patients with eosinophilic esophagitis: a post hoc analysis.
  
    Dellon E, Collins M, Katzka D, Mukkada V, Falk G, Zhang W
    
    
    Therap Adv Gastroenterol. 2024; 17:17562848241307602.
  
  
    PMID: 39735351
    
          PMC: 11672502.
    
          DOI: 10.1177/17562848241307602.
      
 
                                          
                                                          
  Salivary Metabolomic Signatures in Pediatric Eosinophilic Esophagitis.
  
    Hiremath G, Codreanu S, Sherrod S, Tyree R, Correa H, Choksi Y
    
    
    Allergy. 2024; 80(1):354-358.
  
  
    PMID: 39707873
    
          PMC: 11724226.
    
          DOI: 10.1111/all.16450.
      
 
                                          
                                                          
  Biologics for eosinophilic oesophagitis: a systematic review and meta-analysis.
  
    Zeng B, Jia D, Li S, Liu X, Zhu B, Zhang Y
    
    
    Ann Med. 2024; 57(1):2445192.
  
  
    PMID: 39707826
    
          PMC: 11703371.
    
          DOI: 10.1080/07853890.2024.2445192.
      
 
                                          
                                                          
  Canadian Society of Allergy and Clinical Immunology position statement: panel testing for food allergies.
  
    Al Ghamdi A, Abrams E, Carr S, Hanna M, Herman S, Lavine E
    
    
    Allergy Asthma Clin Immunol. 2024; 20(1):61.
  
  
    PMID: 39614376
    
          PMC: 11607807.
    
          DOI: 10.1186/s13223-024-00937-0.
      
 
                                          
                                                          
  Meta-Analysis: Evaluating Placebo Rates Across Outcomes in Eosinophilic Oesophagitis Randomised Controlled Trials.
  
    Rivas A, Ahmed N, Yuan Y, Qasim A, OGorman D, Feagan B
    
    
    Aliment Pharmacol Ther. 2024; 61(1):32-43.
  
  
    PMID: 39543931
    
          PMC: 11636190.
    
          DOI: 10.1111/apt.18382.
      
 
                                          
                                                          
  Health-Related Quality of Life and Perceived Stigma in Eosinophilic Esophagitis: A Real-World, US, Web-Based Survey.
  
    Gold B, Goodwin B, Davis K, Sweeney C, Reynolds M, Jiang J
    
    
    Gastro Hep Adv. 2024; 3(8):1087-1097.
  
  
    PMID: 39529648
    
          PMC: 11550744.
    
          DOI: 10.1016/j.gastha.2024.07.015.
      
 
                                          
                                                          
  Real world treatment patterns in patients with eosinophilic esophagitis in Japan.
  
    Sawada A, Ihara Y, Imai T, Tanaka F, Fujiwara Y
    
    
    Sci Rep. 2024; 14(1):27490.
  
  
    PMID: 39528636
    
          PMC: 11555047.
    
          DOI: 10.1038/s41598-024-78868-4.
      
 
                                          
                                                          
  Pharmacologic Treatment of Eosinophilic Esophagitis: Efficacious, Likely Efficacious, and Failed Drugs.
  
    Schoepfer A, Safroneeva E
    
    
    Inflamm Intest Dis. 2024; 9(1):199-209.
  
  
    PMID: 39474328
    
          PMC: 11521425.
    
          DOI: 10.1159/000540275.
      
 
                                          
                                                          
  Treatment Preference Archetypes in Eosinophilic Esophagitis and Their Implications for Therapy.
  
    Chang J, Brophy K, Ryan K, Rubenstein J, Dellon E, Wallner L
    
    
    Am J Gastroenterol. 2024; 120(1):173-181.
  
  
    PMID: 39422324
    
          PMC: 11695144.
    
          DOI: 10.14309/ajg.0000000000003133.
      
 
                                          
                                                          
  From Pathogenesis to Treatment: Targeting Type-2 Inflammation in Eosinophilic Esophagitis.
  
    Barchi A, Mandarino F, Yacoub M, Albarello L, Massimino L, Savarino E
    
    
    Biomolecules. 2024; 14(9).
  
  
    PMID: 39334846
    
          PMC: 11429508.
    
          DOI: 10.3390/biom14091080.
      
 
                                          
                                                          
  Budesonide Oral Suspension: Expanding the Toolkit for Eosinophilic Esophagitis.
  
    Chang J, Dellon E, Mukkada V
    
    
    Am J Gastroenterol. 2024; 120(1):16-19.
  
  
    PMID: 39311427
    
          PMC: 11695148.
    
          DOI: 10.14309/ajg.0000000000003090.
      
 
                                          
                                                          
  Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants: A Randomized Phase 1 Study.
  
    Prokopienko A, Wang J, Yajnik V, Baratta M, Desai N, Richmond C
    
    
    J Clin Pharmacol. 2024; 65(2):217-225.
  
  
    PMID: 39263900
    
          PMC: 11771711.
    
          DOI: 10.1002/jcph.6131.
      
 
                                          
                                                          
  Esophageal Candidiasis Is Strongly Associated With Treatment Response to Topical Steroids in Eosinophilic Esophagitis and Could Be a Marker of Adherence.
  
    Cameron B, Xue A, Kiran A, LaFata S, Ocampo A, McCallen J
    
    
    Gastro Hep Adv. 2024; 3(5):612-614.
  
  
    PMID: 39165420
    
          PMC: 11330905.
    
          DOI: 10.1016/j.gastha.2024.03.003.